Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis

Trial Profile

MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Azathioprine; Cyclophosphamide; Prednisone
  • Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
  • Focus Therapeutic Use
  • Acronyms MAINRITSAN
  • Most Recent Events

    • 19 Oct 2018 According to a Genentech media release, this trial is supported by Roche.
    • 19 Oct 2018 According to a Genentech media release, based on the data from this trial, U.S. Food and Drug Administration (FDA) has approved an update to the Rituxan (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) who have achieved disease control with induction treatment.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top